Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution
Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 2
Abstract
Quantification of target site pharmacokinetics (PK) is crucial for drug discovery and development. Clinical micro-dialysis (MD) has increasingly been employed for the description of drug distribution and receptor phase PK of the unbound fraction of various analytes. Costs for MD experiments are comparably low and given suitable analytics, target tissue PK of virtually any drug molecule can be quantified. The major limitation of MD stems from the fact that organs such as brain, lung or liver are not readily accessible without surgery. Recently, non-invasive imaging techniques, i.e. positron emission tomography (PET) or magnetic resonance spectroscopy (MRS), have become available for in vivo drug distribution assessment and allow for drug concentration measurements in practically every human organ. Spatial resolution of MRS imaging, however, is low and although PET enables monitoring of regional drug concentration differences with a spatial resolution of a few millimetres, discrimination between bound and unbound drug or parent compound and metabolite is difficult. Radiotracer development is furthermore time and labour intensive and requires special expertise and radiation exposure and costs originating from running a PET facility cannot be neglected. The recent complementary use of MD and imaging has permitted to exploit individual strengths of these diverse techniques. In conclusion, MD and imaging techniques have provided drug distribution data that have so far not been available. Used alone or in combination, these methods may potentially play an important role in future drug research and development with the potential to serve as translational tools for clinical decision making.
Authors and Affiliations
Martin Brunner, Oliver Langer
Keywords
Related Articles
- EP ID EP681777
- DOI 10.1007/BF02854896
- Views 73
- Downloads 0
Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice
Elevated basal concentrations of glucagon and reduced postprandial glucagon suppression are partly responsible for the increased hepatic glucose production seen in type 2 diabetic patients. Recently, it was demonstrated...
Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: Studies with cyclosporine A
Lipoproteins are a heterogeneous population of macromolecular aggregates of lipids and proteins that are responsible for the transport of lipids through the vascular and extravascular fluids from their site of synthesis...
Assessment of a Spectrophotometric Assay for Monoacylglycerol Lipase Activity
N-arachidonyl maleimide, methylarachidonyl fluorophosphonate, and arachidonoyl-1-thio-glycerol were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). 5,5′-dithiobis(2-dinitrobenzoic acid) and 2-oleoylg...
Quality by Design: Concepts for ANDAs
Quality by design is an essential part of the modern approach to pharmaceutical quality. There is much confusion among pharmaceutical scientists in generic drug industry about the appropriate element and terminology of q...
Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics
Monoclonal antibodies (mAbs) as a class of therapeutic molecules are finding an increasing demand in the biotechnology industry for the treatment of diseases like cancer and multiple sclerosis. A key challenge associated...